31 January 2024 - In partnership with Sumitomo, Pfizer is proud to announce that supply of Myfembree (relugolix 40 mg, estradiol 1 mg and norethisterone acetate 0.5 mg tablets) is now available in Canada by prescription for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, as well as for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

As previously announced, Pfizer will lead commercialisation efforts of Myfembree for both the uterine fibroid and endometriosis indications in Canada.

Read Sumitomo press release